reports
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule ...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to seven (7) new employees to purchase 161,600 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rul...
Full House Resorts Announces Third Quarter Earnings Release Date
Full House Resorts Announces Third Quarter Earnings Release Date LAS VEGAS, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Full House Resorts (NASDAQ: FLL) announced today that it will report its third quarter 2025 financial results on Thursday, November 6, 2025, followed by a conference call at 2:00 p.m. ET (11:00 a.m. PT). Investors can access the live audio webcast from the Company’s website at under the investor relations section. The conference call can also be accessed by dialing (201) 689-8470. A replay of the conference call will be available shortly after the conclusion of the call through ...
RGC Resources, Inc. Declares Quarterly Dividend
RGC Resources, Inc. Declares Quarterly Dividend ROANOKE, Va., Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (Nasdaq: RGCO) declared a quarterly dividend of $0.2075 per share on the Company’s common stock. The dividend will be paid on November 3, 2025 to shareholders of record on October 17, 2025. This is the Company’s 326th consecutive quarterly cash dividend. RGC Resources, Inc. provides energy and related products and services to customers in Virginia through its operating subsidiaries including Roanoke Gas Company and RGC Midstream, L.L.C. The state...
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Mul...
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 6 years of continuous treatment, with no new safety signals emerging with prolonged treatment NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced updated d...
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Slee...
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation) and Avadel Pharmaceuticals are celebrating five years of collaboration and dedicated support for early-career sleep researchers and future sleep physicians. In 2021, Avadel became the Young Investigator Research Forum’s (YIRF) inaugural corporate sponsor. Thanks to support from Avadel and other companies, YIRF has empowered dozens of trainees and junior faculty in sleep and circadi...
Interparfums, Inc. Elects Two New Board Members and Announces Annual M...
Interparfums, Inc. Elects Two New Board Members and Announces Annual Meeting Results NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Interparfums, Inc. (NASDAQ GS: IPAR) today announced the results of the matters voted upon at its Annual Meeting of Shareholders held on Wednesday, September 10, 2025, including the election of two new members to its Board of Directors. Shareholders approved of all proposals presented at the meeting, as follows: 1. Election of Directors – Shareholders elected a Board of Directors consisting of eleven (11) members to serve until the Company’s next annual meeti...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule ...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to five (5) new employees to purchase 165,520 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rul...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® ...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 24 - 26, 2025 in Barcelona, Spain. ...
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollme...
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimens NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the company’s anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis (RMS). BRIUMVI is currently approved in the United States, as well as several ex-US territories, as a one-hour intravenous (IV) infusion administered twice...
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate)...
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025 – 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – REFRESH study also highlights efficacy in those who were new to oxybate or returning to oxybate after discontinuing twice-nightly oxybate – DUBLIN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company f...
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Glob...
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ET NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, being held in New York, NY on September 8 – 10, 2025. The fireside chat is scheduled to take place on Monday, September 8, 2025, at 10:30am ET. A live webcast of the fires...
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclu...
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd – Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia – – Initial pharmacokinetic (PK) and comparative bioavailability study to initiate in fourth quarter 2025 with pivotal PK trial planned for second half 2026 – – XWPharma to receive $20 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales – DUBLIN and...
TG Therapeutics Announces Completion of Existing Share Repurchase Prog...
TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that it has completed its previously authorized $100 million share repurchase program, which was initially announced in August 2024. Under that program, the Company repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share. In addition, the Company’s Board of Directors has authorized a new share repurchase program to...
Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthca...
Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2025, at 1:05 p.m. ET. A live webcast of the presentation will be available on the “Investors” section of the Company’s website at and will be available for replay on that site fol...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference: Fireside chat on Friday, September 5 at 11:00 a.m. ET.Morgan Stanley 23rd Annual Global Healthcare Conference: Fireside chat on Tuesday, September 9 at 1:05 p.m. ET.H.C. Wainwright 27th Annual Global Investment C...
TG Therapeutics to Participate in the Cantor Global Healthcare Confere...
TG Therapeutics to Participate in the Cantor Global Healthcare Conference Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global Healthcare Conference, being held in New York, NY on September 3 - 5, 2025. The fireside chat is scheduled to take place on Wednesday, September 3, 2025, at 10:20am ET. A live webcast of the fireside chat will be available on the Even...
RGC Resources, Inc. Reports Third Quarter Earnings
RGC Resources, Inc. Reports Third Quarter Earnings ROANOKE, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated earnings of $538,412, or $0.05 per share, for the third quarter ended June 30, 2025, compared to $156,692, or $0.02 per share, for the fiscal quarter ended June 30, 2024. The increase during the quarter was largely the result of higher earnings from the Company’s investment in the Mountain Valley Pipeline, LLC (“MVP”). CEO Paul Nester stated, “We continue to honor our mission of creating value for shareholders and our community by pr...
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growt...
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Tuesday, August 12, 2025, at 2:00 p.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the “Investors” section of the Company’s website at and will be available for...
Full House Resorts Announces Second Quarter Results
Full House Resorts Announces Second Quarter Results - American Place Casino Continued Its Strong Growth, Achieving Record Net Revenue and Operating Profit - Colorado Operations Reported a 7.8% Increase in Revenue Compared to the Prior-Year Period - Revamped Marketing Efforts at Chamonix Began in the Third Quarter; Focused Cost Reductions at the Property in the Second Quarter are Expected to Produce $4 Million in Annualized Savings LAS VEGAS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Full House...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule ...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to eight (8) new employees to purchase 60,400 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.